Hanmi Pharm, "Sanofi Decides to Return Rights for Diabetes Drug Efpeglenatide"

[Asia Economy Reporter Eunmo Koo] Hanmi Pharm announced on the 9th that its partner Sanofi has decided to return the rights of the diabetes drug Epeglenatide, secured through a contract signed on November 5, 2015, back to Hanmi Pharm. Sanofi notified Hanmi Pharm of its intention to return the rights of Epeglenatide on May 13, and after 120 days of consultation according to their agreement, the two companies finalized the return of rights. Hanmi Pharm will not return the contract payment of 200 million euros (approximately 264.3 billion KRW) already received even after the rights are returned.